Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12187804 | 0.74 | CYP1A2 (0.49) | METCYP3A4TSHRCYP2C19CASR | |
| SCHEMBL18355415 | 0.72 | FGFR1 (0.37) | METALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL9906168 | 0.71 | CASR (0.54) | CYP3A4TSHRCYP2C19CASRALDH1A1 | |
| SCHEMBL1329308 | 0.70 | ALDH1A1 (0.55) | METTSHRPABPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3391025 | 0.70 | TGFBR1 (0.45) | METCYP3A4TSHRCYP2C19KDM4C | |
| SCHEMBL16132924 | 0.69 | DOT1L (0.48) | ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL11432364 | 0.68 | KMT2A (0.46) | CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL17035971 | 0.68 | MET (0.43) | METPABPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17035960 | 0.68 | DOT1L (0.50) | CYP3A4PABPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL249404 | 0.68 | KMT2A (0.55) | CYP3A4TSHRCYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-20160213677-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239883-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | MET 3487/4885CYP3A4 101/4885TSHR 3567/4885 |
| US-20160213677-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | MET 3487/4885CYP3A4 101/4885TSHR 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.